IMR Press / FBL / Volume 14 / Issue 7 / DOI: 10.2741/3410

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
A Web-based platform for interdisciplinary biomedical research
Show Less
1 eHealth-systems, Biomedical Engineering, Austrian Research Centers GmbH-ARC, Graz, Austria
2 CCRI, St. Anna Children’s Hospital, Vienna, Austria
Academic Editor:Haseeb Ahmad Khan
Front. Biosci. (Landmark Ed) 2009, 14(7), 2738–2746; https://doi.org/10.2741/3410
Published: 1 January 2009
(This article belongs to the Special Issue Molecular biology in clinical practice)
Abstract

The European Neuroblastoma Group of the International Society for Paediatric Oncology (SIOPEN) is dedicated to the research and treatment of neuroblastoma. The medical research network SIOPEN-R-NET is an extensive web-based European IT network for interdisciplinary biomedical research. The IT infrastructure has been built using state-of-the-art multi-tiered architecture principles. Basic features required for electronic data capture in clinical trials were implemented. Additionally, advanced tools were developed for registration, review, user management, communication and image management. Currently three clinical trials and eight supporting scientific studies are implemented. The medical research network is already in use by 345 active users from 240 institutions in 18 countries. More than 960 000 item entries and 7962 images from 1260 patients are stored. Challenges, which resulted from the fact that only 16 % of the centres had more than 2 patients per year, have been addressed by an intuitive user interface, hierarchical roles, user required features, and experienced support. The system has already been used extensively and has helped to make significant progress in the area of Neuroblastoma research.

Share
Back to top